{"id":"W2026940417","doi":"10.1007/s10637-014-0139-9","title":"A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"ca_institutions":"Juravinski Cancer Centre; University of Alberta","funders":"","keywords":"Afatinib; Pemetrexed; Medicine; Oncology; Maximum tolerated dose; Internal medicine; Pharmacology; Chemotherapy; Cisplatin; Cancer; Gefitinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001741024,0.001836118,0.003260775,0.0005069212,0.0005484993,0.001710199,0.001337391,0.001868283,0.005621273],"category_scores_gemma":[0.001585411,0.0007779199,0.002490422,0.0006411869,0.001634971,0.002392638,0.0005105613,0.006598702,0.001202728],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001644056,"about_ca_system_score_gemma":0.00149519,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001136904,"about_ca_topic_score_gemma":0.002692842,"domain_scores_codex":[0.9993941,0.0002071882,0.00003126715,0.0001796331,0.00004343374,0.0001444576],"domain_scores_gemma":[0.9988924,0.0002142025,0.0001653675,0.0001337043,0.00006064854,0.0005337654],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8839504,0.03002247,0.002639085,0.0005757696,0.002140903,0.0001392753,0.0002948983,0.003459173,0.01358801,0.0004495558,0.003996008,0.05874445],"study_design_scores_gemma":[0.8496159,0.1420093,0.003849539,0.00002174497,0.0003888137,0.0001584427,0.00006916555,0.001217204,0.00100769,0.0003910756,0.001239084,0.0000320788],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9914331,0.001985318,0.0005508211,0.00108919,0.0003489664,0.001373042,0.001240777,0.0001097808,0.001868947],"genre_scores_gemma":[0.9898899,0.001292657,0.001587617,0.001151266,0.0001762321,0.001395532,0.002221901,0.00004913829,0.002235801],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005621273,"threshold_uncertainty_score":0.01880509,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008347684921314954,"score_gpt":0.287026971593901,"score_spread":0.2786792866725861,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}